Clinical Trial Update: Pharmacokinetic-pharmacodynamic Interaction Between BIA 3-202 and Levodopa/Carbidopa [Phase 1]

View source ↗

Summary

Phase 1 study evaluating the pharmacokinetic–pharmacodynamic interaction between BIA 3-202 and levodopa/carbidopa in Parkinson's disease. The trial has complete…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Parkinson Disease

Drugs mentioned

• BIA 3-202
• Levodopa/Carbidopa (levodopa/carbidopa)

Snippet

Sponsor: Bial - Portela C S.A. | Conditions: Parkinson's Disease | Phase 1 | Status: COMPLETED